Moderna Surpasses Q1 Revenue Estimates Driven by International Vaccine Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: Newsfilter
- International Revenue Surge: Moderna's Q1 international revenue reached $311 million, significantly outpacing the $78 million from U.S. markets, demonstrating strong sales driven by partnerships in the UK, Canada, and Australia, thereby balancing its revenue structure between international and domestic markets.
- Vaccine Policy Impact: Major changes in U.S. vaccine policy have led to reduced vaccine usage, with Moderna's CFO expressing hope for a more stable market moving forward, anticipating a recovery in the U.S. COVID market by 2026, which will influence the company's long-term strategy.
- Strong Financial Performance: Moderna reported Q1 revenue of $389 million, an increase of $281 million year-over-year, exceeding analysts' expectations of $228 million, indicating robust performance in the vaccine market and a recovery in demand.
- New Product Development: The company is expanding its product line with plans for an mRNA flu vaccine and developing a personalized cancer vaccine in partnership with Merck, as well as treatments for rare metabolic disorders, showcasing its strategic shift in the post-pandemic era.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 46.060
Low
17.00
Averages
32.47
High
63.00
Current: 46.060
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Partners with CEPI to Develop Ebola Vaccine
- Vaccine Development Partnership: Moderna announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine against the Bundibugyo ebolavirus linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo, highlighting the company's proactive role in addressing global health crises.
- Funding Commitment: Under the agreement, CEPI has committed up to $50 million to support the preclinical development and early clinical testing of Moderna's investigational BDBV vaccine candidate, aiming to accelerate the vaccine's path to market.
- Diverse Investment Strategy: CEPI also plans to initially invest $8.6 million in a vaccine developed by the University of Oxford and manufactured by the Serum Institute of India, along with $3.2 million for a vaccine developed by the International AIDS Vaccine Initiative, reflecting a commitment to multiple vaccine development efforts.
- Global Health Strategy: The World Health Organization recommended prioritizing several experimental drugs, including antibodies, antivirals, and vaccines for the treatment and prevention of BDBV last week, aligning CEPI's efforts with global public health strategies aimed at addressing future epidemic threats.
See More
Moderna and Merck's Cancer Vaccine Shows Significant Efficacy in Late-Stage Melanoma
- Clinical Trial Results: Moderna and Merck's experimental cancer vaccine intismeran autogene combined with Keytruda demonstrated a 49% reduction in the risk of recurrence or death and a 50% reduction in distant metastasis risk in high-risk late-stage melanoma patients, indicating the potential efficacy of this therapy.
- Long-Term Follow-Up Data: Based on a median five-year follow-up of the phase 2 KEYNOTE-942/mRNA-4157-P201, overall survival showed a positive trend, further validating the long-term efficacy and safety of the vaccine.
- Expansion Potential: Intismeran autogene, known as an mRNA individualized neoantigen therapy, is also being investigated for other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma, showcasing its broad application prospects.
- Market Impact and Outlook: This breakthrough data could enhance the market competitiveness of Moderna and Merck in the field of cancer immunotherapy, attracting more investments and accelerating the progression of subsequent clinical trials.
See More
WHO Meets Congo President to Address Ebola Outbreak
- Outbreak Larger Than Reported: The WHO reported 906 suspected Ebola cases in Congo, with 223 deaths under investigation, while the government confirmed 282 cases and 42 deaths, indicating the outbreak is significantly more severe than official figures suggest, impacting public health safety.
- Call for International Support: WHO Director-General Tedros urged the international community to provide more support in Congo to control the outbreak, emphasizing the importance of early detection, case isolation, and community awareness to ensure effective pandemic response.
- Vaccine Development Acceleration: Global health organization CEPI will provide approximately $60 million to Moderna and two other groups to accelerate the development of vaccines against the Ebola Bundibugyo strain, with trials potentially ready within months, enhancing response capabilities.
- Medical Team Assistance: China announced it would send a team of medical specialists to assist in combating the outbreak in Congo, while four nurses have been discharged from the hospital after recovery, indicating initial success in treatment measures and boosting public confidence.
See More
The Importance of Market Capitalization for Investors
- Market Capitalization Comparison: Moderna Inc (MRNA) has a market cap of $18.88 billion compared to Generac Holdings Inc (GNRC) at $16.45 billion, allowing investors to accurately assess the relative value of both companies and avoid misleading judgments based on stock prices alone.
- Impact on Investor Decisions: Market capitalization not only affects a company's ranking among peers but also directly influences which mutual funds and ETFs are willing to hold the stock; for instance, funds focused on large-cap stocks may only be interested in companies valued at over $10 billion, impacting capital inflows.
- Significance of MidCap Index: The S&P MidCap index focuses on smaller “up-and-coming” companies by excluding the largest 100 firms, enabling investors to discover potential high-growth opportunities, highlighting the importance of market capitalization in investment strategies.
- Stock Price Fluctuation Observation: At Friday's close, MRNA was down about 0.8% while GNRC fell about 0.4%, reflecting ongoing market attention to the relative values of both companies, prompting investors to closely monitor market dynamics for informed decision-making.
See More
EMA Recommends Targeting XFG Variant for 2026/2027 Vaccines
- Vaccine Development Focus: The European Medicines Agency (EMA) has recommended that vaccine manufacturers target the SARS-CoV-2 variant XFG for the 2026/2027 immunization campaign, reflecting a proactive approach to current epidemiological trends aimed at enhancing vaccine efficacy.
- Variant Prevalence: As of October 2025, XFG accounted for 74% of infections, demonstrating its dominance among JN.1 subvariants, and the EMA's recommendation aims to address this prevalence to ensure vaccines are both targeted and effective.
- International Collaboration: The EMA made its recommendation in consultation with the World Health Organization and international partners, ensuring that the perspectives of vaccine manufacturers were considered, which reflects the EMA's global outlook and collaborative spirit in vaccine development.
- FDA Support for Adjustment: An FDA advisory panel voted 8-0 to support adjusting the next round of COVID vaccines to reflect the XFG variant, indicating that this variant made up over 50% of U.S. cases, further underscoring the necessity for vaccine adjustments.
See More
FDA Panel Recommends Updating COVID Vaccines for XFG Variant
- Vaccine Update Recommendation: The FDA advisory panel voted 8-0 to recommend updating COVID vaccines for the 2026-27 season to target the XFG variant, which now accounts for over half of COVID cases in the U.S., despite concerns about limited data from some members.
- Variant Impact: Known as 'Stratus', the XFG variant carries mutations that may help it partially evade existing antibody protection, highlighting the urgency of updating vaccines to address the evolving virus landscape.
- Manufacturing Capability: Briefing documents revealed that manufacturers like Moderna, Pfizer-BioNTech, and Novavax confirmed their ability to produce updated vaccines in time for the 2026-27 season, ensuring continuity in vaccine supply.
- Policy Background Shift: The relatively calm discussion during the meeting contrasts sharply with the turbulence surrounding federal vaccine policy since Robert F. Kennedy Jr. became Health Secretary, indicating a potential new direction for the FDA in vaccine policy.
See More
Moderna Partners with CEPI to Develop Ebola Vaccine
- Vaccine Development Partnership: Moderna announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine against the Bundibugyo ebolavirus linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo, highlighting the company's proactive role in addressing global health crises.
- Funding Commitment: Under the agreement, CEPI has committed up to $50 million to support the preclinical development and early clinical testing of Moderna's investigational BDBV vaccine candidate, aiming to accelerate the vaccine's path to market.
- Diverse Investment Strategy: CEPI also plans to initially invest $8.6 million in a vaccine developed by the University of Oxford and manufactured by the Serum Institute of India, along with $3.2 million for a vaccine developed by the International AIDS Vaccine Initiative, reflecting a commitment to multiple vaccine development efforts.
- Global Health Strategy: The World Health Organization recommended prioritizing several experimental drugs, including antibodies, antivirals, and vaccines for the treatment and prevention of BDBV last week, aligning CEPI's efforts with global public health strategies aimed at addressing future epidemic threats.
See More
Moderna and Merck's Cancer Vaccine Shows Significant Efficacy in Late-Stage Melanoma
- Clinical Trial Results: Moderna and Merck's experimental cancer vaccine intismeran autogene combined with Keytruda demonstrated a 49% reduction in the risk of recurrence or death and a 50% reduction in distant metastasis risk in high-risk late-stage melanoma patients, indicating the potential efficacy of this therapy.
- Long-Term Follow-Up Data: Based on a median five-year follow-up of the phase 2 KEYNOTE-942/mRNA-4157-P201, overall survival showed a positive trend, further validating the long-term efficacy and safety of the vaccine.
- Expansion Potential: Intismeran autogene, known as an mRNA individualized neoantigen therapy, is also being investigated for other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma, showcasing its broad application prospects.
- Market Impact and Outlook: This breakthrough data could enhance the market competitiveness of Moderna and Merck in the field of cancer immunotherapy, attracting more investments and accelerating the progression of subsequent clinical trials.
See More
WHO Meets Congo President to Address Ebola Outbreak
- Outbreak Larger Than Reported: The WHO reported 906 suspected Ebola cases in Congo, with 223 deaths under investigation, while the government confirmed 282 cases and 42 deaths, indicating the outbreak is significantly more severe than official figures suggest, impacting public health safety.
- Call for International Support: WHO Director-General Tedros urged the international community to provide more support in Congo to control the outbreak, emphasizing the importance of early detection, case isolation, and community awareness to ensure effective pandemic response.
- Vaccine Development Acceleration: Global health organization CEPI will provide approximately $60 million to Moderna and two other groups to accelerate the development of vaccines against the Ebola Bundibugyo strain, with trials potentially ready within months, enhancing response capabilities.
- Medical Team Assistance: China announced it would send a team of medical specialists to assist in combating the outbreak in Congo, while four nurses have been discharged from the hospital after recovery, indicating initial success in treatment measures and boosting public confidence.
See More
The Importance of Market Capitalization for Investors
- Market Capitalization Comparison: Moderna Inc (MRNA) has a market cap of $18.88 billion compared to Generac Holdings Inc (GNRC) at $16.45 billion, allowing investors to accurately assess the relative value of both companies and avoid misleading judgments based on stock prices alone.
- Impact on Investor Decisions: Market capitalization not only affects a company's ranking among peers but also directly influences which mutual funds and ETFs are willing to hold the stock; for instance, funds focused on large-cap stocks may only be interested in companies valued at over $10 billion, impacting capital inflows.
- Significance of MidCap Index: The S&P MidCap index focuses on smaller “up-and-coming” companies by excluding the largest 100 firms, enabling investors to discover potential high-growth opportunities, highlighting the importance of market capitalization in investment strategies.
- Stock Price Fluctuation Observation: At Friday's close, MRNA was down about 0.8% while GNRC fell about 0.4%, reflecting ongoing market attention to the relative values of both companies, prompting investors to closely monitor market dynamics for informed decision-making.
See More
EMA Recommends Targeting XFG Variant for 2026/2027 Vaccines
- Vaccine Development Focus: The European Medicines Agency (EMA) has recommended that vaccine manufacturers target the SARS-CoV-2 variant XFG for the 2026/2027 immunization campaign, reflecting a proactive approach to current epidemiological trends aimed at enhancing vaccine efficacy.
- Variant Prevalence: As of October 2025, XFG accounted for 74% of infections, demonstrating its dominance among JN.1 subvariants, and the EMA's recommendation aims to address this prevalence to ensure vaccines are both targeted and effective.
- International Collaboration: The EMA made its recommendation in consultation with the World Health Organization and international partners, ensuring that the perspectives of vaccine manufacturers were considered, which reflects the EMA's global outlook and collaborative spirit in vaccine development.
- FDA Support for Adjustment: An FDA advisory panel voted 8-0 to support adjusting the next round of COVID vaccines to reflect the XFG variant, indicating that this variant made up over 50% of U.S. cases, further underscoring the necessity for vaccine adjustments.
See More
FDA Panel Recommends Updating COVID Vaccines for XFG Variant
- Vaccine Update Recommendation: The FDA advisory panel voted 8-0 to recommend updating COVID vaccines for the 2026-27 season to target the XFG variant, which now accounts for over half of COVID cases in the U.S., despite concerns about limited data from some members.
- Variant Impact: Known as 'Stratus', the XFG variant carries mutations that may help it partially evade existing antibody protection, highlighting the urgency of updating vaccines to address the evolving virus landscape.
- Manufacturing Capability: Briefing documents revealed that manufacturers like Moderna, Pfizer-BioNTech, and Novavax confirmed their ability to produce updated vaccines in time for the 2026-27 season, ensuring continuity in vaccine supply.
- Policy Background Shift: The relatively calm discussion during the meeting contrasts sharply with the turbulence surrounding federal vaccine policy since Robert F. Kennedy Jr. became Health Secretary, indicating a potential new direction for the FDA in vaccine policy.
See More
